TAK-935 (OV935)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TAK-935 (OV935), covering 2021-02-18 to 2021-02-18. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies [Phase 2]